A carregar...
Adverse Events Associated With PCSK9 Inhibitors: A Real‐World Experience
In randomized clinical trials (RCTs) proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors showed a favorable safety profile, however, “real‐world” data on adverse events (AEs) is scarce. Three datasets, a hospital registry (n = 164), and two Pharmacovigilance databases, Lareb (n = 149) and Vi...
Na minha lista:
| Publicado no: | Clin Pharmacol Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6704355/ https://ncbi.nlm.nih.gov/pubmed/30053327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|